Showing results (11-20 of 296) with videos related to
Sort By:
Pageof 30
Biometrics|August 21, 2003
Continual reassessment method for ordered groupsJohn O'Quigley, Xavier PaolettiRadiation Research|March 26, 2015
Mortality from Circulatory System Diseases among French Uranium Miners: A Nested Case-Control StudyDamien Drubay, Sylvaine Caër-Lorho, Pierre Laroche, et al.Critical Reviews in Oncology/Hematology|August 23, 2002
EORTC prostate cancer trials: what have we learnt?Theo M de Reijke, Laurence ColletteEuropean Urology|November 23, 2006
Implications of prostate-specific antigen doubling time as indicator of failure after surgery or radiation therapy for prostate cancerMassimo Maffezzini, Alberto Bossi, Laurence ColletteRadiation and Environmental Biophysics|May 27, 2014
Kidney cancer mortality and ionizing radiation among French and German uranium minersDamien Drubay, Sophie Ancelet, Alain Acker, et al.Statistical Methods in Medical Research|April 5, 2019
An adaptive design for the identification of the optimal dose using joint modeling of continuous repeated biomarker measurements and time-to-toxicity in phase I/II clinical trials in oncologyMaria-Athina Altzerinakou, Xavier PaolettiStatistics in Medicine|February 9, 2021
Change-point joint model for identification of plateau of activity in early phase trialsMaria-Athina Altzerinakou, Xavier PaolettiInternational Journal of Cancer|June 12, 2003
Induced and spontaneous abortion and breast cancer risk: results from the E3N cohort studyXavier Paoletti, Françoise Clavel-ChapelonEuropean Journal of Cancer (Oxford, England : 1990)|May 30, 2006
Prostate-specific antigen (PSA) alone is not an appropriate surrogate marker of long-term therapeutic benefit in prostate cancer trialsLaurence Collette, Tomasz Burzykowski, Fritz H SchröderThe Journal of Pathology|October 6, 2021
Multilayer spectrum of intratumoral heterogeneity in basal bladder cancerNanor Sirab, Damien Drubay, Pascale Maillé, et al.Pageof 30